Epperly Melissa B,
- SEC CIK
- 0001807359
In the past year, 4 open-market sale filings worth $2.65M and no purchases.
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $2.65M
- 4 filings
- Net
- −$2.65M
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Epperly Melissa B, as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
ROIV Roivant Sciences Ltd.
Director4 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 5, 2026 (view filing)6:05 PM ET | Oct 1 | 4 days | Epperly Melissa B,Director | SSale | −17.8K | $36.10 | −$640.9K | −54.3%15.0K after | 2 lots10b5-1 |
| Sep 17, 2026 (view filing)6:43 PM ET | Sep 15 | 2 days | Epperly Melissa B,Director | SSale | −4.94K | $39.74 | −$196.2K | −33.3%9.90K after | 2 lots10b5-1 |
| Jul 1, 2026 (view filing)6:34 PM ET | Jun 29 | 2 days | Epperly Melissa B,Director | SSale | −17.8K | $34.38 | −$610.3K | −51.9%16.5K after | 2 lots10b5-1 |
| Mar 18, 2026 (view filing) | Mar 16 | 2 days | Epperly Melissa B,Director | SSale | −41.9K | $28.68 | −$1.20M | −72.6%15.8K after |
ZNTL Zentalis Pharmaceuticals, Inc.
Chief Financial Officer8 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 12, 2024 (view filing) | Feb 12 | Same day | Epperly Melissa B,Chief Financial Officer | SSale | −2.57K | $11.44 | −$29.4K | −0.6%451.4K after | |
| Feb 5, 2024 (view filing) | Feb 2 | 3 days | Epperly Melissa B,Chief Financial Officer | SSale | −8.67K | $11.54 | −$100.0K | −1.9%454.0K after | |
| Oct 6, 2023 (view filing) | Oct 4 | 2 days | Epperly Melissa B,Chief Financial Officer | SSale | −5.48K | $19.51 | −$106.9K | −1.4%387.7K after | 2 lots10b5-1 |
| Feb 14, 2023 (view filing) | Feb 13-14 | 1 day | Epperly Melissa B,Chief Financial Officer | SSale | −7.85K | $20.13 | −$158.0K | −2.0%392.0K after | 2 lots |
| Apr 5, 2022 (view filing) | Apr 4 | 1 day | Epperly Melissa B,Chief Financial Officer | SSale | −17.1K | $50.09 | −$855.6K | −6.5%247.4K after | 5 lots |
| Feb 23, 2022 (view filing) | Feb 23 | Same day | Epperly Melissa B,Chief Financial Officer | SSale | −1.91K | $49.10 | −$93.9K | −0.7%264.5K after | 2 lots |
| Aug 20, 2021 (view filing) | Aug 18-19 | 2 days | Epperly Melissa B,Chief Financial Officer | PPurchase | +9.61K | $52.00 | +$499.8K | +3.7%266.7K after | 2 lots |
| Jul 6, 2021 (view filing) | Jul 1 | 5 days | Epperly Melissa B,Chief Financial Officer | SSale | −3.08K | $51.27 | −$158.1K | −1.2%257.1K after | 4 lots |